2004 (15 POSTS)

Tice RR, Choksi NY, Allen DG, Haseman JH, Hill R, Lewis M, et al. Estimation of the underprediction rates for the in vivo rabbit dermal corrosion assay. Poster presented at Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

View Abstract

Choksi NY, Haseman JH, Allen DG, Tice RR, Stokes WS. Estimation of the underprediction rates for the in vivo rabbit dermal irritation assay. Poster presented at Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

View Abstract

Urban JD, Gay EA, Mailman RB. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. 2004. Perfluorooctane sulfonate (PFOS) alters lung development in the neonatal rat. Birth Defects Res A 70(5):42.

2003 (9 POSTS)

Haws L. Combustion risk modeling and assessment. Presented at the Texas Commission on Environmental Quality Workshop on Hazardous Waste Combustion, Austin, TX, May 2003.

Perry CS. Process for development of protective concentration levels for remediation sites in Texas. Presented at Society for Environmental Toxicology and Chemistry (SETAC) meeting, Austin, TX, November 2003.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. A comparison of the metabolism of methoxyresorufin, acetanilide, and caffeine in rat and human CYP1A2 SUPERSOMES, Society of Toxicology 42nd Annual Meeting, Salt Lake City, UT, 2003.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. Caffeine, acetanilide, and methoxyresorufin metabolism by rat and human CYP1A2 SUPERSOMES and their inhibition by 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD). Dioxin 2003, Boston, MA, 2003. Organohalogen Compounds 64:324-327.

View Abstract

Grasty RC, Grey BE, Lau CS, Rogers JM. 2003. Window of susceptibility to perfluorooctane sulfonate (PFOS)-induced neonatal mortality in the rat. Birth Defects Research B 68(3):5.

Panko JM. Mold problems in buildings. Solving water intrusion and mold problems in Pennsylvania. Lorman Education Services, Altoona, PA, November 5, 2003.

Panko JM. AWMA/Healthy indoor partnerships. International Conference on Indoor Air Quality/Health Indoor Environment, Mold Contamination Case Studies, 2003.

Panko JM, Shay EC, Unice KM. Risk perception: The reoccupancy of Lower Manhattan office space following the national tragedies of September 11, 2001. Poster at the Society for Risk Analysis Annual Conference, December 2003.

Clewell H, Crump K, Covington T, Gentry R, Yeager J. A risk assessment for inhaled arsenic based on urinary arsenic concentration using a pharmacokinetic model. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2003.

2002 (7 POSTS)

Haws L. Permitting of hazardous waste combustion facilities in the state of Texas: Human health risks associated with fugitive emissions sources. Presented at the Texas Chemical Council Quarterly Meeting. Houston, TX, August 2002.

Haws L. Texas risk reduction program rule-The basics. Question and Answer Forum Panelist. Presented at the Texas Natural Resource Conservation Commission Environmental Trade Fair. Waste Remediation Track, Austin, TX, May 2002.

Haws L. Toxicology and risk assessment resources and practices in the state of Texas. Presented at the USEPA Region 6 States Risk Assessment Roundtable, Dallas, TX, April 2002.

Perry CS. TRRP Rule – The basics part 2: Human health PCLs and look-up tables. TNRCC Environmental Trade Fair presentation and paper, 2002.

Grasty RC, Grey BE, Thibodeaux J, Lau C, Rogers JM. Critical period for increased neonatal mortality induced by perfluorooctane sulfonate (PFOS) in the rat. Society of Toxicology 41st Annual Meeting, Nashville, TN, March 2002.

Staskal DF, DeVito MJ, Ross DG, Birnbaum LS. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. Society of Toxicology 41st Annual Meeting, Nashville, TN, March 2002.

Gentry R, Teeguarden J, Sarangapani R, Covington T, Lawrence G, McDonald T, Shipp A, Clewell H. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences in tissue dosimetry. Poster presented at the Society of Toxicology Annual Meeting, Nashville, TN, March 2002.